Clinical Significance of PD‐L1 and HLA Expression in Esophageal Squamous Cell Carcinoma in Response to Immunotherapy
Kosuke Kanemitsu, Yoshiyuki Tagayasu, Yoshihiro Komohara, Cheng Pan, Rin Yamada, Yukio Fujiwara, Kazuto Harada, Keisuke Kosumi, Yoshifumi Baba, Masaaki Iwatsuki · 2026
Read Clinical Significance of PD‐L1 and HLA Expression in Esophageal Squamous Cell Carcinoma in Response to Immunotherapy by Kosuke Kanemitsu, Yoshiyuki Tagayasu, Yoshihiro Komohara, Cheng Pan, Rin Yamada, Yukio Fujiwara, Kazuto Harada, Keisuke Kosumi, Yoshifumi Baba, Masaaki Iwatsuki (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13394168.txt.
Description
Immune checkpoint drugs have changed the outlook for esophageal squamous cell cancer, but many patients still do not respond. Kosuke Kanemitsu and co-authors search tumor samples from forty-five treated patients for signs that separate responders from the rest. They stain the samples for immune markers, the PD-L1 signal, and the HLA molecules that present targets to immune cells.
High PD-L1 on tumor cells and on the macrophages around them marked the patients who benefited. Those tumors also drew in more T cells, though cell counts alone did not predict response. Responders oddly showed less of one HLA family and stray amounts of another. Gene data from single cells linked macrophage PD-L1 to T-cell growth. The authors argue both marker families belong in prediction tests.
Catalog record
| CREATOR | Kosuke Kanemitsu, Yoshiyuki Tagayasu, Yoshihiro Komohara, Cheng Pan, Rin Yamada, Yukio Fujiwara, Kazuto Harada, Keisuke Kosumi, Yoshifumi Baba, Masaaki Iwatsuki |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |